Nonalcoholic Fatty Liver Disease

Caldwell, Stephen H.; Argo, Curtis K.; Al‐Osaimi, Abdullah

doi:10.1002/9781119950509.ch32

Cited by 9 publications

(8 citation statements)

References 426 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While liver biopsy is the gold standard for confirmation, grading, and staging of NAFLD (Yan, Durazo, Tong, & Hong, 2007), only a small percentage of persons have liver biopsies due to the risk of bleeding (Caldwell, Argo, & Al-Osaimi, 2012). Liver function tests, such as ALT and AST, may be elevated in persons with NAFLD triggering an evaluation for NAFLD.…”

Section: Background and Significancementioning

confidence: 99%

Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease

et al. 2013

View full text Add to dashboard Cite

Background Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent condition strongly associated with obesity that can result in premature death. Little is known about a symptoms experience in this progressive disease, preventing health care providers from intervening in the early stages. Purpose This study explicated symptoms in persons with NAFLD at higher risk of disease progression defined as the presence of one or two copies of the PNPLA3 gene, (rs738409)-G allele. Method Guided by the Symptoms Experience Model, 42 persons >21 years of age with diagnosed NAFLD were recruited from Western Michigan specialty offices in this cross-sectional descriptive study design. The Memorial Symptom Assessment Scale was used to measure the symptoms experience. Discussion Participants (97%) experienced 1 or more symptoms (average number of symptoms 12.02, SD 8.817). There was no statistically significant relationship between symptoms and the PNPLA3 (rs738409) variants. Significant predictors of mean frequency, severity and distress of symptoms [TMSAS] (F=2.609; df1=15, df2=25; p=.016) were identified. Conclusion Persons with NAFLD experience an average of 12 symptoms.

show abstract

Section: Background and Significancementioning

confidence: 99%

Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases in the whole world [1]. The pathogenesis of NAFLD can be explained by the multi-hit theory in which metabolic syndrome and fat deposition in the liver (the first hit) sensitize the liver tissue to inflammatory mediators (second hit), resulting in fibrosis [2,3]. These inflammatory mediators include proinflammatory cytokines, endotoxins from the intestinal flora, and oxidative stress [4].…”

Section: Introductionmentioning

confidence: 99%

Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study

El-Aziz

Alnaggar

Nabih

et al. 2020

ceh

View full text Add to dashboard Cite

Aim of the study: This study aimed to assess the level of serum Mac-2 binding protein (Mac-2BP) as a non-invasive biomarker for the diagnosis of non-alcoholic fatty liver disease (NAFLD). Material and methods: Forty patients with NAFLD and 15 healthy sex-and age-matched subjects were included in this pilot study. Serum Mac-2BP level was measured using ELISA. Liver biopsy was taken from 20 patients. Results: There was no statistically significant difference between patients and controls regarding the level of Mac-2BP (p = 0.209). Mac-2BP had a statistically significant correlation with the grade of lobular inflammation (r = 0.464, p = 0.039). The Mac-2BP cutoff value used for NASH prediction was 9.55 µg/ml, with sensitivity and specificity of 100% and 91.7%, respectively. Conclusions: This study showed that Mac-2BP is not elevated in NAFLD patients compared to controls. It also demonstrated that the reliability of Mac-2BP as a biomarker for NAFLD diagnosis is still controversial and needs more investigation.

show abstract

“…For example, almost all patients with NAFLD, including both NNFL and NASH, have some component of insulin resistance and metabolic syndrome [35] . However, within this population there may be subpopulations with different courses and expectations for comorbidity and mortality.…”

Section: Heterogeneity Of the Nafld And Nash Populations?mentioning

confidence: 99%

The Natural History of Non-Alcoholic Fatty Liver Disease

Caldwell¹,

Argo²

2010

Dig Dis

156

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease has a variable prognosis which is predictable to an extent based on the presence or absence of histological liver injury. Past studies have determined a number of clinical and laboratory parameters which predict greater severity on the initial biopsy, although all of these measures have limitations and biopsy remains the gold standard at this time. For patients with early stage non-alcoholic steatohepatitis (NASH), about one third will progress to stage 3 or 4 (cirrhosis) over 5–10 years. Thus, early-stage NASH constitutes one of the groups most likely to benefit from treatments now undergoing investigation. Among those who progress to NASH cirrhosis, about 25% will develop major complications of portal hypertension within 3 years. In contrast, non-NASH fatty liver tends to be stable over time, although there appears to be an increased cancer risk in all forms of fatty liver, albeit greater in NASH compared to non-NASH fatty liver. Interestingly, the cause of death among patients with NASH is more often due to cardiovascular disease or non-liver malignancy than cirrhosis. However, the accelerated risk of cirrhosis in this group compared to cardiovascular disease suggests that this picture is likely to change in the foreseeable future. Meanwhile, the relationship between these comorbidities will increasingly lead to patients with both coronary disease or malignancy and NASH-related cirrhosis presenting clinicians with a very challenging set of problems in coming years.

show abstract

Nonalcoholic Fatty Liver Disease

Cited by 9 publications

References 426 publications

Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease

Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease

Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study

The Natural History of Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About